Journal article

Investigating the Efficacy of Triple Artemisinin-Based Combination Therapies for Treating Plasmodium falciparum Malaria Patients Using Mathematical Modeling

Saber Dini, Sophie Zaloumis, Pengxing Cao, Ric N Price, Freya J Fowkes, E Rob W van der Pluijm, James M McCaw, Julie A Simpson

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | AMER SOC MICROBIOLOGY | Published : 2018

Abstract

The first line treatment for uncomplicated falciparum malaria is artemisinin-based combination therapy (ACT), which consists of an artemisinin derivative coadministered with a longer-acting partner drug. However, the spread of Plasmodium falciparum resistant to both artemisinin and its partner drugs poses a major global threat to malaria control activities. Novel strategies are needed to retard and reverse the spread of these resistant parasites. One such strategy is triple artemisinin-based combination therapy (TACT). We developed a mechanistic within-host mathematical model to investigate the efficacy of a TACT (dihydroartemisinin-piperaquine-mefloquine [DHA-PPQ-MQ]) for use in South-East ..

View full abstract

Grants

Awarded by NHMRC Centres for Research Excellence in Malaria Elimination


Awarded by Victorian Center for Biostatistics, Infectious Diseases Modeling


Awarded by NHMRC


Awarded by ARC Discovery Project


Funding Acknowledgements

This study was supported by the NHMRC Centres for Research Excellence in Malaria Elimination (1134989), Victorian Center for Biostatistics (1035261), Infectious Diseases Modeling to Inform Public Health Policy (1078068), an NHMRC Project Grant (1100394), and an ARC Discovery Project (DP170103076). F.J.I.F. was supported by Australian Research Council Future Fellowship. R.N.P. is a Wellcome Trust Senior Fellow in Clinical Science (200909), and J.A.S. is a NHMRC Senior Research Fellow (1104975).